Pattern of HCV Genotypes in HIV/HCV Co-Infected Patients on Antiretroviral Therapy in Nigeria

Azuka Patrick Okwuraiwe, Akinniyi Adediran Osuntoki, Osaretin Albert Ebuehi and Rosemary Ajuma Audu
Additional contact information
Azuka Patrick Okwuraiwe: Nigerian Institute of Medical Research, Nigeria
Akinniyi Adediran Osuntoki: University of Lagos, Nigeria
Osaretin Albert Ebuehi: University of Lagos, Nigeria
Rosemary Ajuma Audu: Nigerian Institute of Medical Research, Nigeria

European Journal of Medical and Health Sciences, 2022, vol. 4, issue 5, 30-34

Abstract: At least 33 million people worldwide are living with human immunodeficiency virus (HIV) infection, and about 20-30% of these are also infected with hepatitis C virus (HCV). Co-infection with HIV and HCV is a major public health concern. Co-infected persons develop cirrhosis and end-stage liver disease more quickly than individuals infected with HCV only. The particular HCV strain or genotype is a major factor for HCV prognosis. The pattern of HCV genotypes in a cohort of HIV/HCV co-infected patients was investigated. One hundred (100) adult patients were recruited from the Nigerian Institute of Medical Research (NIMR), Yaba, Lagos, with age ranging from 18 to 65 years (58% male). Upon recruitment, they were placed on appropriate antiretroviral drugs; 300 mg tenofovir (TDF), 200 mg emtricitabine (FTC) plus 600 mg efavirenz (EFV) once daily dosage. HCV genotyping was done using the Linear Array hepatitis C virus genotyping kit (Roche Molecular Systems, Inc. USA). HCV genotyping revealed prevalence of genotypes 1 (65.6%) and 4 (34.4%), respectively. These are the hard-to-treat genotypes that previously required a long duration of HCV therapy until newer drugs were introduced. The nature of HCV genotypes in HIV/HCV co-infected people has serious implications for further HCV therapy. These findings are pertinent for decisions about the best possible time for and kind of HCV treatment in the setting of co-morbid HIV infection.

Keywords: HCV genotype; HIV-; co-infection; antiretroviral (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/ejmed/article/view/41372 Abstract page (text/html)
https://eu-opensci.org/index.php/ejmed/article/download/41372/9579 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:ejmed0:v:4:y:2022:i:5:id:41372

DOI: 10.24018/ejmed.2022.4.5.1372

Access Statistics for this article

More articles in European Journal of Medical and Health Sciences from European Open Science
Bibliographic data for series maintained by Support ().